Compare
Context Therapeutics Inc. vs Spero Therapeutics, Inc. vs Corvus Pharmaceuticals, Inc. vs Rallybio Corp
| Latest fiscal year | Context Therapeutics Inc. CNTX | Spero Therapeutics, Inc. SPRO | Corvus Pharmaceuticals, Inc. CRVS | Rallybio Corp RLYB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $66.80M | n/a | $858.0K |
| Revenue growth (YoY) | n/a | +39.2% | n/a | +34.9% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | 9.5% | n/a | n/m |
| Net margin | n/a | 12.8% | n/a | n/m |
| Net income | -$36.12M | $8.57M | -$15.28M | -$8.98M |
| EPS (Diluted) | -$0.38 | $0.15 | -$0.53 | -$1.59 |
| Operating cash flow | -$26.39M | -$12.62M | -$32.80M | -$29.81M |
| Free cash flow | -$26.42M | n/a | -$32.97M | n/a |
| Cash & equivalents | $66.00M | $40.27M | $4.58M | $31.37M |
| Total assets | $68.49M | $68.92M | $71.12M | $62.26M |
| Total liabilities | $8.02M | $9.90M | $9.91M | $4.30M |
| Shareholders' equity | $60.47M | $59.02M | $61.20M | $57.96M |
| Return on year-end equity | -59.7% | 14.5% | -25.0% | -15.5% |
| Shares outstanding | 91.88M | 56.41M | 74.70M | 5.28M |
Revenue, most recent five fiscal years
| Fiscal year | Context Therapeutics Inc. | Spero Therapeutics, Inc. | Corvus Pharmaceuticals, Inc. | Rallybio Corp |
|---|---|---|---|---|
| Latest | n/a | $66.80M Ended 2025-12-31 | n/a | $858.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $47.98M Ended 2024-12-31 | n/a | $636.0K Ended 2024-12-31 |
| 2 years earlier | n/a | $103.78M Ended 2023-12-31 | n/a | n/a |
| 3 years earlier | n/a | $53.51M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $18.26M Ended 2021-12-31 | n/a | n/a |